The International Neuromodulation Society

The Fastest-Growing, Worldwide Multidisciplinary Body Devoted to Building Knowledge of Neuromodulation

The International Neuromodulation Society (INS) is a non-profit group of clinicians, scientists and engineers dedicated to the scientific development and awareness of neuromodulation – the alteration of nerve activity through targeted delivery of a stimulus, such as electrical stimulation or chemical agents, to specific neurological sites in the body. The San Francisco-based INS was formed in 1989 and educates and promotes the field through meetings, its peer-reviewed journal Neuromodulation: Technology at the Neural Interface, explanatory content, and chapter websites. The INS also provides information for patients and produces rolling news briefs about this rapidly evolving field.

The INS Peer-Reviewed Journal – 8 Issues a Year

The INS journal Neuromodulation: Technology at the Neural Interface has a growing Impact Factor and is indexed in Index Medicus, MEDLINE and Pubmed from its first issue in 1998. Members may log in to the members-only section to read the journal online.

journal cover

+Submit a Manuscript.+

What is Neuromodulation?

Medical Professionals can learn about various considerations concerning neuromodulation and clinic contacts. Once your preliminary questions have been answered, please use the Contact Us facility to find out more and to discuss specific objectives. Others may simply wish to join the INS and one of its related chapter societies, please use the Membership Application.

Clinical trials that involve a wide range of emerging neuromodulation approaches are listed on our Research page. Neuromodulation clinical trials address symptom control through nerve stimulation in such condition categories as:

If you are not a medical professional and you are searching for information about neuromodulation and how these types of treatment could benefit a specific condition such as treatment-resistant headache or other chronic pain syndromes, you may find the sections titled Therapies, About Neuromodulation or FAQs particularly helpful.

Members may log in and visit the members-only section’s Global Discussion Forum

Breaking News Share

Review: Transcranial Magnetic Stimulation for Anxiety

Sept. 23, 2019 - An article surveys the scientific literature on transcranial magnetic stimulation for anxiety. (Dove Press)

First Patient Implant Announced for Company's Brain-Machine Interface Device

Sept. 20, 2019 - Synchron announced implantation of the first patient with its brain-machine interface device, which has an electrode that is threaded like a stent through an artery to sense electrical activity in the motor cortex using electrocoricography. The company is endeavoring to develop the device as a way for people with paralysis to communicate through directing the brain-machine interface to create text messages. (Fierce Biotech)

News Coverage Features Neuromodulation for Pain in Capital of Saskatchewan, Canada

Sept. 20, 2019 - An article about access to spinal cord stimulation in Regina, Saskatchewan, Canada, encourages awareness among referrers and patients about the treatment and about the influence of wait times on outcomes. (Global News)

Presentation: Deep Transcranial Magnetic Stimulation for Obsessive Compulsive Disorder

Sept. 20, 2019 - A presentation at a European conference about applied brain research, ECNP 2019, covered data from a randomized, sham-controlled, double-blind clinical trial of high-frequency deep transcranial magnetic stimulation for obsessive compulsive disorder. The trial's stimulation targets were the anterior cingulate cortex and medial prefrontal cortex. (Clinical Psychiatry News)

Deep Brain Stimulation Outpatient Service Opens in Metropolitan Region of Southern India

Sept. 19, 2019 - A Bengaluru-based hospital will establish a monthly outpatient clinic for deep brain stimulation to serve people in the area with Parkinson's disease. (Deccan Herald)

Registry Tracks Outcomes of Intrathecal Drug Delivery in Cancer Pain

Sept. 18, 2019 - An analysis presents prospective data from a multicenter product surveillance registry that began adding patient-reported outcomes of intrathecal drug delivery for cancer pain in 2013. (Anesthesia & Analgesia)

To see select neuromodulation news by category, as well as news about the INS in particular, please visit the Newsroom. To see archived news briefs dating back to January 2011, visit the News Archive.

Continue Reading News Briefs
Last Updated on Monday, December 12, 2016 10:01 AM